MJMorten Daniel Jensen

Morten Daniel Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Morten Daniel Jensen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence and Mortality of Community‐Acquired Sepsis or Bacteraemia in Patients With Alcohol‐Related Cirrhosis

    by Clara Juul Stenderup, Margarita Dudina, Kirstine Kobberøe Søgaard, Morten Daniel Jensen, Peter Jepsen

    Background & Aims: Liver cirrhosis is associated with an increased risk of bacterial infections, but there is a lack of reliable population‐based data to quantify this risk. We examined the incidence and predictors of community‐acquired serious systemic infections. Methods: This was a population‐based study that included all patients in the Central Denmark Region diagnosed with alcohol‐related cirrhosis (ALD cirrhosis) in 2013–2022. We computed the cumulative incidence of community‐acquired serious systemic infections, encompassing sepsis and bacteraemia. We used Fine & Gray regression to investigate predictors of infection within the first year. Results: We included 2511 patients with ALD cirrhosis (69.3% males, median age 61 years, median MELD‐NA score 13). Their cumulative risk of a first‐time community‐acquired serious systemic infection was 3.8% (95% CI: 3.1–4.6) after 1 year and 5.9% (95% CI: 5.0–6.9) after 3 years. The most frequent causative pathogens were Enterobacterales (38%), Staphylococci (25%) and Streptococci (22%). Increasing MELD‐Na score at cirrhosis diagnosis was associated with an increased risk of serious systemic infection within the first year after diagnosis (subdistribution hazard ratio = 1.05, 95% CI: 1.02–1.08, per 1 point increase). The 30‐day all‐cause mortality was 30% (95% CI: 23–37) following hospitalization with a serious systemic infection. Conclusions: This population‐based study determined the risk and mortality of serious systemic infections in ALD cirrhosis. Our findings will be important for future studies of interventions to prevent infections.

  • Open Access

    Cholangiocarcinoma in Denmark: time trends in mortality following resection

    by Morten D. Jensen, Joe West, Britta Weber, Alice Markussen, Frank V. Mortensen, Peter Jepsen

    Background: Cholangiocarcinomas have a poor prognosis, and resection is the only curative-intent treatment. We examined time trends in mortality risk after resection in a nationwide Danish cohort. Methods: We identified all Danish citizens diagnosed with cholangiocarcinoma in 2004–2022 who subsequently underwent liver resection, biliary tract resection, or a combination of the two. We computed the proportions of patients who received downstaging or adjuvant chemotherapy, and we estimated age- and sex-adjusted mortality risks. Results: Between 2004 and 2022, 611 patients with cholangiocarcinoma underwent resection (13% of 4572 patients with cholangiocarcinoma). The proportion who underwent resection increased from 9% in 2004–2012 to 16% in 2018–2022, the median age of resected patients rose from 65 to 69 years, and the proportion with comorbidities increased from 17% to 28%. In patients who underwent liver resection, the proportion who had received downstaging chemotherapy increased from P -value = 0.37). In patients who underwent biliary tract resection, only 3% received downstaging chemotherapy, but the proportion who received adjuvant therapy increased from 17% (10–29) in 2004–2012 to 59% (48–68) in 2018–2022. Even so, these patients’ age- and sex-adjusted mortality remained stable (1-year mortality ranging from 19% to 24%, P -value = 0.34). Conclusion: The proportion of patients with cholangiocarcinoma who underwent liver or biliary tract resection increased, and more patients received downstaging chemotherapy and adjuvant chemotherapy. Nonetheless, age- and sex-adjusted mortality risks remained constant. The explanations for this pattern are unclear but likely involve changing patient characteristics other than age and sex.

  • Open Access

    Cholangiocarcinoma in Denmark: Time-trends in incidence and mortality

    by Morten Daniel Jensen, Joe West, Britta Weber, Frank Viborg Mortensen, Peter Jepsen


  • Response: Proton Pump Inhibitors and Alcohol‐Related Cirrhosis

    by Marine Sølling Ramsing, Morten Daniel Jensen, Peter Jepsen

  • Open Access

    Use of Proton Pump Inhibitors Among Patients With Alcohol‐Related Cirrhosis—A Danish Nationwide Cohort Study

    by Marine Sølling Ramsing, Morten Daniel Jensen, Peter Jepsen

    Background: Use of proton pump inhibitors (PPIs) may have adverse effects in patients with alcohol‐related cirrhosis (ALD cirrhosis), but PPIs continue to be used by many patients. Aims: We aimed to describe the prevalence and incidence of PPI use from filled prescriptions among patients with ALD cirrhosis and to identify predictors of PPI initiation after ALD cirrhosis diagnosis. Methods: We used Danish nationwide healthcare registries to investigate PPI use among patients diagnosed with ALD cirrhosis from 1997 to 2022. We used multivariable Cox regression to identify predictors of PPI initiation. Results: We identified 41 263 patients diagnosed with ALD cirrhosis in 1997–2022. In this cohort, the prevalence of PPI use rose to 40% in 2016 and plateaued at this level through 2022. Considering time since diagnosis, 26% were using PPI at the diagnosis of ALD cirrhosis, and the prevalence peaked at 38% 3 months later. Among PPI users, 79% used more than 30 defined daily doses per year on average during the follow‐up. Patients older than 50 years were more likely than younger patients to initiate PPI treatment. Conclusion: The use of PPIs continues to be prevalent among patients with ALD cirrhosis, with 40% of all patients using PPIs in 2022. Within the first 3 months after diagnosis, 38% of all patients were using PPIs. Our results provide essential background information for future RCTs on the risks and benefits of prescribing or deprescribing PPIs.


  • Open Access

    Lactulose use among patients with alcohol-related liver cirrhosis as a surrogate marker of hepatic encephalopathy: prevalence and association with mortality - a Danish nationwide cohort study

    by Emma Celia Herting, Morten Daniel Jensen, Peter Jepsen

    Background & aims: Hepatic encephalopathy (HE), one of the most serious prognostic factors for mortality in alcohol-related cirrhosis (ALD cirrhosis), is not recorded in Danish healthcare registries. However, treatment of HE with lactulose, the universal first-line treatment, can be identified through data on filled prescriptions. This study aimed to investigate if lactulose can be used as a surrogate marker of HE. Methods: We used Danish healthcare registries to establish a cohort of patients with ALD cirrhosis diagnosed in 2000–2018. Lactulose users were identified using data on filled prescriptions. We computed the prevalence and cumulative incidence of lactulose use, and then matched lactulose users with cohort members who were not using lactulose. This matched dataset was used to identify predictors of lactulose initiation, and to examine the association between lactulose use and all-cause mortality. Results: We included 23,089 patients, among whom we identified 4,789 first-time lactulose users. The prevalence of lactulose usage rose to 11% within the first 6 months after ALD diagnosis and reached 19% 5 years after inclusion. The 1-year cumulative incidence of lactulose use was 31%, and predictors of initiating lactulose use were history of severe liver disease (ascites, portal hypertension, spontaneous bacterial peritonitis or gastrointestinal bleeding) or hepatocellular carcinoma. Lactulose use was associated with higher mortality (adjusted hazard ratio 1.61 [95% confidence interval 1.53; 1.69]). Conclusions: Lactulose is used by 10–20% of patients with ALD cirrhosis, primarily those with severe cirrhosis, and lactulose users have a markedly higher mortality than nonusers. We conclude that lactulose use can be used to estimate the prevalence of HE and to reduce confounding from HE, but it should not be used as a surrogate for HE in studies with HE as an outcome.


  • Primary Liver Cancer Risk and Mortality in Patients With Alcohol-Related Cirrhosis in England and Denmark: Observational Cohort Studies

    by Morten Daniel Jensen, Joe West, Colin Crooks, Joanne R. Morling, Frederik Kraglund, Tim Card, Gro Askgaard, Peter Jepsen

    INTRODUCTION: Patients with alcohol-related cirrhosis (ALD cirrhosis) have an increased risk of primary liver cancer (hepatocellular carcinoma [HCC] or intrahepatic cholangiocarcinoma [iCCA]). England recommends surveillance for HCC in these patients, while Denmark does not. METHODS: We performed an observational cohort study using the English Clinical Practice Research Datalink and the nationwide Danish healthcare registries to identify 17,110 English (2000–2016) and 22,122 Danish (1994–2022) patients with diagnosis codes of ALD cirrhosis. We computed and compared incidence rates and cumulative incidence of primary liver cancer, annual ultrasound scan rates, and mortality following diagnosis of primary liver cancer. RESULTS: The overall risk of primary liver cancer was similar in England and Denmark: 5-year risk was 2.24% (95% confidence interval 2.00–2.49) in England (iCCA 0.07%, HCC 2.16%) and 2.36% (2.15–2.57) in Denmark (iCCA 0.05%, HCC 2.30%). The annual rate of ultrasound scans per person was 0.65 (0.63–0.67) in England and 0.44 (0.42–0.46) in Denmark. The 1-year mortality after a diagnosis of primary liver cancer was 59.2% (54.4–64.0) in England and 60.9% (57.4–64.4) in Denmark. The 3-year risks of HCC in those on vs off surveillance in England were 2.3% (1.0–4.6) vs 1.5% (1.0–2.2). DISCUSSION: The risk of primary liver cancer was the same in English and Danish patients with ALD cirrhosis, and HCCs constituted 97% of primary liver cancers. Mortality with primary liver cancer was equally high in both countries. Notably, in England, where guidance recommends biannual HCC surveillance with ultrasound, patients with ALD cirrhosis were undergoing fewer than 1 ultrasound scan per year.


  • Open Access

    Population-Based Study of Alcohol-Related Liver Disease in England in 2001–2018: Influence of Socioeconomic Position

    by Gro Askgaard, Peter Jepsen, Morten Daniel Jensen, Anna Emilie Kann, Joanne Morling, Frederik Kraglund, Tim Card, Colin Crooks, Joe West

    INTRODUCTION: England has seen an increase in deaths due to alcohol-related liver disease (ALD) since 2001. We studied the influence of socioeconomic position on the incidence of ALD and the mortality after ALD diagnosis in England in 2001–2018. METHODS: This was an observational cohort study based on health records contained within the UK Clinical Practice Research Datalink covering primary care, secondary care, cause of death registration, and deprivation of neighborhood areas in 18.8 million residents. We estimated incidence rate and incidence rate ratios of ALD and hazard ratios of mortality. RESULTS: ALD was diagnosed in 57,784 individuals with a median age of 54 years and of whom 43% had cirrhosis. The ALD incidence rate increased by 65% between 2001 and 2018 in England to reach 56.1 per 100,000 person-years in 2018. The ALD incidence was 3-fold higher in those from the most deprived quintile vs those from the least deprived quintile (incidence rate ratio 3.30, 95% confidence interval 3.21–3.38), with reducing inequality at older than at younger ages. For 55- to 74-year-olds, there was a notable increase in the incidence rate between 2001 and 2018, from 96.1 to 158 per 100,000 person-years in the most deprived quintile and from 32.5 to 70.0 in the least deprived quintile. After ALD diagnosis, the mortality risk was higher for patients from the most deprived quintile vs those from the least deprived quintile (hazard ratio 1.22, 95% confidence interval 1.18–1.27), and this ratio did not change during 2001–2018. DISCUSSION: The increasing ALD incidence in England is a greater burden on individuals of low economic position compared with that on those of high socioeconomic position. This finding highlights ALD as a contributor to inequality in health.


  • Open Access

    Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study

    by Morten Daniel Jensen, Hugh Watson, Hendrik Vilstrup, Peter Jepsen

    Background and Aims: Previous studies have not been able to determine whether non-selective beta-blockers (NSBB) reduce the risk of sepsis in cirrhosis. We aimed to examine this question with data from 1198 patients with cirrhosis and ascites included in clinical studies of satavaptan, a vasopressin receptor antagonist with no effect on infection risk. Methods: Risk of sepsis was estimated for NSBB users vs nonusers. Patients were examined every four weeks, or in relation to hospitalization, for the one-year duration of the trials. We computed the cumulative risk of sepsis for patients who did vs did not use NSBB at baseline. We used Cox regression to compare hazard rates of sepsis between current users and nonusers, accounting for changes in NSBB use over time. We adjusted for patient sex and age, MELD-Na score, albumin, use of antibiotics, use of proton pump inhibitors, cirrhosis etiology, history of variceal bleeding or SBP, severity of ascites and HE, HCC, other cancers, and diabetes, while stratifying on geographical region. Results: Of the 1198 patients, 54% used NSBB at some time. There were 56 sepsis episodes. The 1-year risk of sepsis was reduced to 5.7% (95% confidence interval [CI] 2.8– 8.6) in baseline NSBB users vs 11.6% (95% CI 7.0– 15.9) in baseline nonusers. The hazard ratio of sepsis for current NSBB users vs current nonusers was reduced to 0.5 (95% CI 0.3– 0.8) and after adjustment to 0.7 (95% CI 0.4– 1.3). Conclusion: NSBB use may reduce the risk of sepsis in patients with cirrhosis and ascites, but the precision of the estimate was limited by the number of episodes of sepsis.


  • Open Access

    Extrahepatic autoimmune diseases in autoimmune hepatitis: Effect on mortality

    by Rasmine Birn‐Rydder, Morten D. Jensen, Peter Jepsen, Lisbet Grønbæk

    Background and Aims: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease associated with an increased prevalence of extrahepatic autoimmune diseases and an increased mortality compared with the general population. The contribution of extrahepatic autoimmune diseases to the increased mortality has not been clarified. Our aim was to determine the effect of extrahepatic autoimmune diseases on mortality in AIH patients.Methods: This nationwide register‐based cohort study included all Danish patients diagnosed with AIH between 1995 and 2019. We examined the presence of extrahepatic autoimmune diseases and compared the mortality between AIH patients with and without extrahepatic autoimmune diseases. We adjusted our analysis for age, sex, calendar year of AIH diagnosis, cirrhosis, cancer, chronic obstructive pulmonary disease and ischaemic heart disease.Results: We included 2479 AIH patients of whom 19.8% had one extrahepatic autoimmune disease and 3.3% had multiple. The adjusted 10‐year cumulative mortality was 27.2% (95% confidence interval [CI]: 25.2–29.4) for patients with extrahepatic autoimmune diseases and 21.6% (95% CI: 19.9–23.6) for patients without. The adjusted mortality hazard ratio was 1.30 (95% CI: 1.12–1.52) for AIH patients with versus without extrahepatic autoimmune diseases; it was 1.25 (95% CI: 1.06–1.48) for patients with one extrahepatic autoimmune disease and 1.54 (95% CI: 1.15–2.05) for those with more than one.Conclusions: Extrahepatic autoimmune diseases increased the mortality in patients with AIH. Patients with multiple extrahepatic autoimmune diseases had a higher mortality than patients with just one extrahepatic autoimmune disease.